Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

被引:25
作者
Kentepozidis, N. [1 ]
Soultati, A. [1 ]
Giassas, S. [2 ]
Vardakis, N. [3 ]
Kalykaki, A. [3 ]
Kotsakis, A. [3 ]
Papadimitraki, E. [3 ]
Pantazopoulos, N. [2 ]
Bozionellou, V. [3 ]
Georgoulias, V. [3 ]
机构
[1] 251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
[2] IASO Gen Hosp, Dept Med Oncol, Athens, Greece
[3] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece
关键词
Prostate cancer; Salvage treatment; Paclitaxel; Carboplatin; DOCETAXEL-BASED CHEMOTHERAPY; MITOXANTRONE PLUS PREDNISONE; ANDROGEN-RECEPTOR GENE; 2ND-LINE TREATMENT; ESTRAMUSTINE; CABAZITAXEL; PROGRESSION; GUIDELINES; CARCINOMA; EFFICACY;
D O I
10.1007/s00280-012-1896-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer. Patients and methods Patients were treated with paclitaxel at the dose of 135 mg/m(2) followed by carboplatin AUC 3 on day 1 every 2 weeks in cycles of 28 days. Results Thirty-eight patients with castration-resistant prostate cancer were enrolled, and all of them had received frontline chemotherapy with docetaxel and prednisone, while 24 (63.2 %) had received 2 or more prior chemotherapy regimens. In an intention-to-treatment analysis, a clinical and/or biochemical response (>50 % decline) was observed in 10 patients (26.3 %; 95 % CI, 12.3-40.3 %), stable disease in 13 (34.2 %) and progressive disease in 15 (39.5 %). The median duration of response was 6.1 months (range, 1.0-9.8), the median time to tumor progression (TTP) 3.6 months (95 % CI, 2.1-5.2) and the median overall survival 9.9 months (95 % CI, 6.2-13.6). The probability for 1-year survival was 43 %. Grade 3 and 4 neutropenia was observed in three (7.9 %) and nine (23.7 %) patients, respectively. Conclusion The biweekly administration of paclitaxel/carboplatin regimen in patients with castration-resistant prostate cancer is an active and well-tolerated regimen which merits to be further evaluated in the context of salvage treatment.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 43 条
  • [1] [Anonymous], ANN ONCOL S8
  • [2] Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life
    Azim, Hatem A., Jr.
    Mok, Tony
    [J]. ANTI-CANCER DRUGS, 2008, 19 (06) : 645 - 653
  • [3] Androgen receptor as a target in androgen-independent prostate cancer - Discussion
    Sartor, O
    Balk, SP
    Brown, M
    [J]. UROLOGY, 2002, 60 (3A) : 138 - 139
  • [4] Beekman Kathleen W, 2005, Clin Prostate Cancer, V4, P86, DOI 10.3816/CGC.2005.n.015
  • [5] A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer
    Berry, William
    Friedland, David
    Fleagle, John
    Jackson, Dori
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    [J]. CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 131 - 137
  • [6] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
    Berthold, Dominik R.
    Pond, Gregory R.
    Soban, Freidele
    de Wit, Ronald
    Eisenberger, Mario
    Tannock, Ian F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 242 - 245
  • [7] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
    Bubley, GJ
    Carducci, M
    Dahut, W
    Dawson, N
    Daliani, D
    Eisenberger, M
    Figg, WD
    Freidlin, B
    Halabi, S
    Hudes, G
    Hussain, M
    Kaplan, R
    Myers, C
    Oh, W
    Petrylak, DP
    Reed, E
    Roth, B
    Sartor, O
    Scher, H
    Simons, J
    Sinibaldi, V
    Small, EJ
    Smith, MR
    Trump, DL
    Vollmer, R
    Wilding, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3461 - 3467
  • [8] Docetaxel Rechallenge in Castration-Resistant Prostate Cancer: Scientific Legitimacy of Common Clinical Practice
    Buonerba, Carlo
    Palmieri, Giovannella
    Di Lorenzo, Giuseppe
    [J]. EUROPEAN UROLOGY, 2010, 58 (04) : 636 - 637
  • [9] Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer
    Cabrespine, A
    Guy, L
    Khenifar, E
    Curé, H
    Fleury, J
    Penault-Llorca, F
    Kwiatkowski, F
    Barthomeuf, C
    Chollet, P
    Bay, JO
    [J]. UROLOGY, 2006, 67 (02) : 354 - 359
  • [10] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
    CALVERT, AH
    NEWELL, DR
    GUMBRELL, LA
    OREILLY, S
    BURNELL, M
    BOXALL, FE
    SIDDIK, ZH
    JUDSON, IR
    GORE, ME
    WILTSHAW, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756